Who is eligible for clinical trial NCT07562152?

Participants must meet protocol criteria for Pancreatic Cancer. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT07562152 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-27

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (NCT07562152)

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Immuneering Corporation

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (5 items).

Location: Clearview Cancer Institute — Huntsville, Alabama

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Must be ≥18 years of age
Must have confirmed diagnosis according to AJCC staging as follows:
Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Participants must be treatment naive as follows:
First-line PDAC participants will have received no previous systemic anti-cancer therapy
Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria
Adequate organ function, hepatic function, coagulation studies and protocol determined clinical laboratory values

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Inability to swallow oral medications
Participant has squamous, adenosquamous, neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma
Participants with only locally advanced disease
Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (41 Sites)

Clearview Cancer Institute — Huntsville, Alabama
City of Hope — Phoenix, Arizona
City of Hope — Duarte, California
Poudre Valley Health Care, Inc — Fort Collins, Colorado
Rocky Mountain Cancer Centers — Lone Tree, Colorado
Medical Oncology Hematology Consultants — Newark, Delaware
Hematology Oncology Associates of the Treasure Coast — Port Saint Lucie, Florida
Florida Cancer Specialists - South — Sarasota, Florida
Florida Cancer Specialists - North — St. Petersburg, Florida
Florida Cancer Specialists - East — West Palm Beach, Florida
Piedmont Cancer Institute — Atlanta, Georgia
Piedmont Healthcare — Atlanta, Georgia
Illinois Cancer Specialists — Arlington Heights, Illinois
City of Hope — Chicago, Illinois
OSF Medical Center — Peoria, Illinois
Maryland Oncology — Columbia, Maryland
Missouri Cancer Associates — Columbia, Missouri
Comprehensive Cancer Centers — Las Vegas, Nevada
Regional Cancer Care — Belleville, New Jersey
NYU Langone Health — New York, New York
Memorial Sloan Kettering Cancer Center — New York, New York
FirstHealth of the Carolinas — Pinehurst, North Carolina
Taylor Cancer Research Center — Maumee, Ohio
Willamette Valley Cancer Institute — Eugene, Oregon
Thomas Jefferson University — Philadelphia, Pennsylvania

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗